NEURANO BIOSCIENCE LLC
Nanoparticle-based gold-memantine conjugate for preferential extrasynaptic NMDA receptor antagonism in opioid use disorder treatment
- Sector
- Biotech
- Headquarters
- La Jolla, CA
- Total capital
- $5.8M
- Federal grants
- $5.8M
- 10 awards · 2019–2025
- Rank in peer group#67 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder$811K
- Federal grantHealth and Human S · Phase II · Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder$838K
- Federal grantHealth and Human S · Phase II · Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder$836K
- Federal grantHealth and Human S · Phase II · Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder$836K
- Federal grantHealth and Human S · Phase I · Alzheimer's disease and novel nanotherapeutics exclusively targeting extrasynaptic NMDA receptors$57K
- Federal grantHealth and Human S · Phase I · Alzheimer's disease and novel nanotherapeuticsexclusively targeting extrasynaptic NMDA receptors$557K
- Federal grantHealth and Human S · Phase I · Alzheimer's disease and novel nanotherapeutics exclusively targeting extrasynaptic NMDA receptors$500K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase I · Pre-clinical evaluation of a rationally designed nanotherapeutic for Huntington's disease$519K
- Federal grantHealth and Human S · Phase I · Pre-Clinical Evaluation of a Rationally Designed Nanotherapeutic for Huntington's Disease$519K
- Federal grantHealth and Human S · Phase I · Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for treatment of opioid use disorders$350K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#67 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- Nanotools BioscienceShares a founder: ELENA MOLOKANOVA
- NANOTOOLS BIOSCIENCE LLCShares a founder: ELENA MOLOKANOVA
- Element 79 Capital Inc.Similar federal contract value in Biotech · null in contracts
- DNALI DATA TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- PHANES BIOTECH, INC.Similar federal contract value in Biotech · null in contracts
- White Dog Labs IncSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .